Payment overview · 2025
General Payments
$599.42
30 reported records · 15 companies
Healthcare provider profile · identity verified
Jerilee Emma Lomas, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · LEHIGH ACRES, FL · NPI 1093889529
Verified facts
What the public records show
CMS Open Payments records show Jerilee Emma Lomas, D.O. received $599.42 in general payments during 2025 across 30 reported records.
GlaxoSmithKline, LLC. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 367 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.05 | 17.0% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $102.00 | 17.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.41 | 13.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.54 | 8.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.49 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.85 | 5.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.22 | 5.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.07 | 4.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.34 | 4.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.46 | 3.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.90 | 3.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.02 | 2.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.47 | 2.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $15.91 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.69 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $599.42 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $102.05 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $102.00 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.49 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.07 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 367 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
32 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
367 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 715 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 168 |
| Lisinopril | Lisinopril | 495 | 161 |
| Metformin Hcl | Metformin Hcl | 425 | 133 |
| Losartan Potassium | Losartan Potassium | 404 | 119 |
| Eliquis | Apixaban | 367 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 119 |
| Gabapentin | Gabapentin | 347 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 302 | 116 |
| Metoprolol Tartrate | Metoprolol Tartrate | 296 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 70 |
| Omeprazole | Omeprazole | 251 | 97 |
| Simvastatin | Simvastatin | 212 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 201 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 46 |
| Montelukast Sodium | Montelukast Sodium | 195 | 66 |
| Alendronate Sodium | Alendronate Sodium | 188 | 60 |
| Sertraline Hcl | Sertraline Hcl | 188 | 55 |
| Trazodone Hcl | Trazodone Hcl | 186 | 58 |
| Atenolol | Atenolol | 178 | 58 |
| Potassium Chloride | Potassium Chloride | 178 | 48 |
| Meloxicam | Meloxicam | 173 | 58 |
| Jardiance | Empagliflozin | 157 | 40 |
| Alprazolam | Alprazolam | 156 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 58 |
| Furosemide | Furosemide | 154 | 41 |
| Carvedilol | Carvedilol | 150 | 33 |
| Ozempic | Semaglutide | 144 | 32 |
| Prednisone | Prednisone | 126 | 75 |
| Methocarbamol | Methocarbamol | 122 | 55 |
| Torsemide | Torsemide | 121 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 38 |
| Glipizide | Glipizide | 101 | 29 |
| Donepezil Hcl | Donepezil Hcl | 100 | 30 |
| Tramadol Hcl | Tramadol Hcl | 100 | 39 |
| Allopurinol | Allopurinol | 96 | 32 |
| Azithromycin | Azithromycin | 95 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 30 |
| Myrbetriq | Mirabegron | 93 | 17 |
| Ezetimibe | Ezetimibe | 91 | 37 |
| Memantine Hcl | Memantine Hcl | 87 | 23 |
| Famotidine | Famotidine | 85 | 34 |
| Xarelto | Rivaroxaban | 81 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 23 |
| Pregabalin | Pregabalin | 73 | 28 |
| Entresto | Sacubitril/Valsartan | 72 | suppressed |
| Glimepiride | Glimepiride | 72 | 28 |
| Spironolactone | Spironolactone | 72 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 30 |
| Fenofibrate | Fenofibrate | 67 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 24 |
| Baclofen | Baclofen | 62 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Metformin Hcl Er | Metformin Hcl | 62 | 21 |
| Warfarin Sodium | Warfarin Sodium | 62 | 11 |
| Mirtazapine | Mirtazapine | 61 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 34 |
| Divalproex Sodium | Divalproex Sodium | 60 | 11 |
| Finasteride | Finasteride | 60 | 21 |
| Buspirone Hcl | Buspirone Hcl | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | 17 |
| Cephalexin | Cephalexin | 55 | 36 |
| Sucralfate | Sucralfate | 55 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 43 |
| Celecoxib | Celecoxib | 53 | 15 |
| Fluconazole | Fluconazole | 51 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 14 |
| Januvia | Sitagliptin Phosphate | 49 | 11 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 48 | 14 |
| Bupropion Xl | Bupropion Hcl | 47 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | 16 |
| Mounjaro | Tirzepatide | 45 | 14 |
| Lorazepam | Lorazepam | 44 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Latanoprost | Latanoprost | 42 | 13 |
| Chlorthalidone | Chlorthalidone | 41 | 16 |
| Clonazepam | Clonazepam | 40 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 40 | 11 |
| Nuplazid | Pimavanserin Tartrate | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 13 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Clonidine Hcl | Clonidine Hcl | 37 | 13 |
| Digoxin | Digoxin | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 20 |
| Lactulose | Lactulose | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Nifedipine Er | Nifedipine | 36 | 13 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 30 |
| Linzess | Linaclotide | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 13 |
| Valsartan | Valsartan | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 30 |
| Meclizine Hcl | Meclizine Hcl | 31 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Neupro | Rotigotine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 11 |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 12 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 17 |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 11 |
| Permethrin | Permethrin | 25 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Temazepam | Temazepam | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 18 |
| Colchicine | Colchicine | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nystatin | Nystatin | 19 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Ivermectin | Ivermectin | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $599.42 · 30 records | GlaxoSmithKline, LLC. | AIRSUPRA, AUSTEDO XR, Arikayce, Brinsupri, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, JARDIANCE, LEQVIO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, VENASEAL, VOQUEZNA, Veozah, Wegovy | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error